Google’s Quantum Echoes runs 13,000× faster than supercomputers

Google Quantum AI announced it has run a complex algorithm called Quantum Echoes on its Willow quantum chip, achieving a computational task 13,000 times faster than the top classical supercomputer.

The company said this is the first verifiable demonstration of quantum advantage for a practical problem on real hardware.

The Quantum Echoes algorithm was used to analyze atomic interactions in real-world molecules, which has applications in fields like chemistry and medical imaging.

Google claims this technology could accelerate research in drug discovery, materials science, and personalized healthcare by allowing faster and more detailed molecular simulations.

The Willow chip used in the experiment features 105 superconducting qubits.

Google said the breakthrough is a step toward creating large-scale, fault-tolerant quantum computers, with the aim of achieving practical applications within five years.

🔗 Source: Google

🧠 Food for thought

Implications, context, and why it matters.

Quantum Echoes delivers verifiable quantum advantage; the 13,000× speedup isn’t about molecules

The 13,000× claim ties to a Quantum Echoes benchmark against Frontier, a top U.S. supercomputer at Oak Ridge National Laboratory, that would take about 150 years classically 1. Quantum Echoes measures chaos growth, not molecular simulations for drug discovery 1.
A second quantum computer can verify this efficiently in principle, which tackles a long challenge, though no independent check has happened yet 1.
A separate preprint applies the method to compute 3D molecular geometry consistent with nuclear magnetic resonance (NMR) data, a technique that infers structure with magnetic fields, though it still trails classical tools 1.
Recent coverage mixes two achievements. One covers a verifiable quantum advantage for chaos measurement, while the other describes a molecular geometry test that is not faster than classical tools.

Pharma and materials companies should monitor hybrid quantum-classical partnerships, not rush pilots

Quantum computing’s drug discovery impact sits years out, with current work in testing rather than full deployment 2.
AstraZeneca runs quantum experiments with IonQ, a trapped-ion hardware provider, which signals early exploration is underway 3.
One pharma firm went back to classical methods after spending $50 million on quantum work with weak results, which underlines the risk of early commitments 2.
R&D and compute leaders in pharma and materials can start with low-cost feasibility tests to check quantum’s fit for specific simulation problems, while tracking hybrid quantum-classical partnerships (collaborations that combine quantum processors with conventional computing) across vendors plus peers 2.